Key result
Vagal nerve stimulation using a novel endovascular spiral lead produced significant heart rate slowing (up to 30.4% decrease at 7 V) compared to a basket catheter in an animal model.
Why the study?
Does vagal nerve stimulation using an endovascular spiral lead reduce heart rate compared to a basket catheter in a canine model?
Does vagal nerve stimulation using an endovascular spiral lead reduce heart rate compared to a basket catheter in a canine model?
A novel endovascular spiral lead for vagal nerve stimulation effectively reduces heart rate in a canine model, demonstrating feasibility for long-term endovascular VNS.
Does not support clinical use of endovascular VNS; leaves open translation from canine models to human therapy.
BACKGROUND: Vagal nerve stimulation (VNS) has negative chronotropic and dromotropic effects. We developed and tested an endovascular spiral vagal stimulation lead (ESVL) designed to follow the projection of the cardiac branches of the vagus nerve around the superior vena cava (SVC) to optimize VNS. METHODS: ESVL contained six 5-mm coil electrodes, spaced 5-mm apart with a spiral guidewire to provide shape. The tightness and diameter of the guidewire were changed before each placement to simulate different lead designs. Various 2-, 3-, and 4-electrode combinations were used and several lead positions were tested each time. Each VNS protocol included 2-12 V, 15-second pulse trains at 20 Hz, with 2 ms pulse duration. A basket catheter (BC) was used as control and to approximate the initial VNS location. The VNS protocol was performed at the optimal location, using first the BC and then several ESVL configurations. RESULTS: VNS caused a voltage-dependent decrease in heart rate (HR). Using the optimal ESVL configuration at 7 V, HR decreased by 30.4% (37.2 bpm) in dog no. 1 and 12.4% (16.6 bpm) in dog no. 2, versus 15.5% (16.6 bpm) and 16.7% (19.5 bpm) with the BC. CONCLUSIONS: A new endovascular spiral lead that takes advantage of the anatomy of the cardiac branches of the vagus nerve in the SVC was developed. VNS using ESVL produced significant HR slowing at voltages slightly below the highest pulse generator output of 7.5 V, which may be suitable for long-term implantation.
No takes yet. Share an insight, caveat, or question.
Nabutovsky et al. (2007) studied Vagal nerve stimulation (animal model) (n=2). Endovascular spiral vagal stimulation lead (ESVL) vs. Basket catheter (BC) was evaluated on Decrease in heart rate (HR). Vagal nerve stimulation using a novel endovascular spiral lead produced significant heart rate slowing (up to 30.4% decrease at 7 V) compared to a basket catheter in an animal model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: